6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October, 2025

Commission File Number: 001-12033

| (Translation of registrant’s name into English) |

Bay & Deveaux Streets, Nassau, The Bahamas

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

As reported previously on September 22, 2025, Nymox Pharmaceutical Corporation (the “Company”) was awarded a percentage of expenses from the 2023 litigation brought by Mr. Lanham, Mr. Riley, CRNSV, and others. The Supreme Court of the Bahamas has issued its final order in that matter and has ordered Mr. Lanham, Mr. Riley, CRNSV, and other claimants to pay the Company $203,075.40.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 22, 2025

| Name: | Paul Averback |

| Title: | President and Chief Executive Officer |